Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice.
Biomaterials
; 33(31): 7775-84, 2012 Nov.
Article
en En
| MEDLINE
| ID: mdl-22828585
ABSTRACT
A hepta-guanidino-ß-cyclodextrin (G-CD), its hepta-PEG conjugate (G-CD-PEG), and the corresponding anisamide-terminated PEG conjugate (G-CD-PEG-AA) have been synthesised and compared as delivery vectors for siRNA to prostate cancer cells and tumours in vivo. The G-CD-PEG-AA.siRNA formulations (in which anisamide targets the sigma receptor), but not the non-targeted formulations, induced prostate cell-specific internalisation of siRNA resulting in approximately 80% knockdown in vitro of the reporter gene, luciferase. Following intravenous administration of the anisamide-targeted formulation in a mouse prostate tumour model significant tumour inactivation with corresponding reductions in the level of vascular endothelial growth factor (VEGF) mRNA were achieved, without demonstrating enhanced toxicity. This data imply significant potential for anisamide-conjugated cyclodextrin vectors for targeted delivery of therapeutic siRNAs in the treatment of prostate cancer.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Benzamidas
/
Técnicas de Transferencia de Gen
/
ARN Interferente Pequeño
/
Beta-Ciclodextrinas
/
Nanopartículas
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
Biomaterials
Año:
2012
Tipo del documento:
Article
País de afiliación:
Irlanda